Exonate fundraises £1.5 million

January 3, 2019

Exonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases.

The announcement marks the closing of its fourth financing round, having raised approximately £9 million in total to date, backed by investment from Angel CoFund, Australian venture fund Uniseed, University of Bristol Enterprise Fund, managed by Parkwalk, Martlet of Cambridge, Wren Capital, and O2h Ventures as well as further Angel investors.

The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases.

You can read the full story on the Pharma Times website here

What are the objectives of the Angel CoFund?
Read FAQs

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london